Nanomaterials to Resolve Atherosclerosis

Area of Science:

• Biomaterial Science
• Nanotechnology
• Cardiovascular Research

Background:

• Cardiovascular disease (CVD) remains the primary global cause of mortality and morbidity.
• Atherosclerosis, characterized by arterial fatty deposits, is a principal driver of CVD.
• Nanomedicine presents a novel therapeutic avenue for managing atherosclerotic plaque.

Purpose of the Study:

• To review the pathophysiology of atherosclerosis.
• To highlight key design parameters for nanomaterials in targeted drug delivery.
• To provide foundational knowledge for biomaterial scientists developing atherosclerosis nanotherapies.

Main Methods:

• Literature review of atherosclerosis pathophysiology.
• Analysis of nanocarrier design principles for atheromatous lesions.
• Synthesis of current research on targeted therapeutic delivery.

Main Results:

• Nanomaterials are essential for targeted and controlled drug release in nanomedicine.
• Nanocarrier design must align with the unique physiochemical properties of atherosclerotic lesions.
• Successful strategies focus on enhancing therapeutic efficacy and lesion resolution.

Conclusions:

• Optimized nanocarrier design is crucial for advancing nanomedicine beyond slowing atherosclerosis progression.
• Tailoring nanomaterials to lesion-specific characteristics enables active plaque resolution.
• This perspective equips scientists to design next-generation nanotherapeutics for atherosclerosis.